Back to top

Analyst Blog

Regeneron Pharmaceuticals, Inc. (REGN - Analyst Report) recently announced that it has received a notification under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act) from Sanofi (SNY - Analyst Report). As per the notification, Sanofi seeks to acquire Regeneron shares through open market and direct shareholder purchases. Sanofi is looking to increase its ownership in Regeneron above the HSR Act notification threshold of $500 million.

Investors have reacted positively to the news. Both Regeneron and Sanofi stocks were up 2.7% and 3.2%, respectively, on the news.

Sanofi and Regeneron have a long standing agreement as per which Sanofi will not acquire more than 30% of Regeneron's class A stock and common stock.

Sanofi and Regeneron collaborate on oncology therapy, Zaltrap (aflibercept). Last week, Sanofi and Regeneron received encouraging news with the European Commission (EC) approving Zaltrap. The EC cleared Zaltrap as a combination therapy (with 5-fluorouracil, leucovorin, irinotecan – FOLFIRI) for treating patients suffering from metastatic colorectal cancer who are either resistant or whose disease has progressed following treatment with an oxaliplatin-containing regimen.

We note that Zaltrap is already approved in the US for the above indication. The US Food and Drug Administration (FDA) approved Zaltrap for the indication in August last year. Approval of Zaltrap in the EU has boosted the drug’s sales potential.

Sanofi and Regeneron both carry a Zacks Rank #2 (Buy). Valeant Pharma (VRX - Analyst Report) and Novo Nordisk (NVO - Analyst Report) are examples of pharma stocks which are more favorably placed. Both companies carry a Zacks Rank #1 (Strong Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
UTD THERAPE… UTHR 117.83 +28.51%
TRIQUINT SE… TQNT 20.67 +6.52%
RF MICRO DE… RFMD 12.47 +6.04%
VASCO DATA… VDSI 14.77 +4.68%
BANCO DO BR… BDORY 15.53 +3.95%